Education
About Us
Working with TipRanks
Follow Us
BioAtla (BCAB)
NASDAQ:BCAB
BCAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.24 - $2.53
Previous CloseN/A
Volume775.41K
Average Volume (3M)682.34K
Market Cap
$21.59M
Enterprise Value$11.01M
Total Cash (Recent Filing)$18.21M
Total Debt (Recent Filing)$6.04M
Price to Earnings (P/E)―
Beta3.51
Next Earnings
Nov 05, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding58,721,590
10 Day Avg. Volume414,208
30 Day Avg. Volume682,335
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue1.00
Enterprise Value/Gross Profit1.07
Enterprise Value/Ebitda-0.17
Forecast
1Y Price Target
$10.00Price Target Upside2464.10% Upside
Rating ConsensusHold
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical TrialsFive patients achieved objective tumor size reductions in various cancer types, including colorectal carcinoma and non-small cell lung cancer.
Drug EfficacyThe drug demonstrated anti-tumor activity in advanced adenocarcinoma patients with a manageable safety profile.
Operational EfficiencyBioAtla reported lower than expected R&D and SG&A expenses, contributing to a better EPS than estimated.
Bears Say
Financial PerformanceBioAtla reported no revenue and a net loss of $0.32 per share, compared to the consensus estimate of a net loss of $0.29 per share.
Pipeline DevelopmentThere are uncertainties regarding BioAtla’s pipeline development and a near-term financial overhang.
Stock ValuationThe price target for BioAtla has been lowered to $1 from $5 based on cash/share and platform value.
BioAtla News
BCAB FAQ
What was BioAtla’s price range in the past 12 months?
BioAtla lowest stock price was $0.24 and its highest was $2.52 in the past 12 months.
What is BioAtla’s market cap?
BioAtla’s market cap is $21.59M.
When is BioAtla’s upcoming earnings report date?
BioAtla’s upcoming earnings report date is Nov 05, 2025 which is in 78 days.
How were BioAtla’s earnings last quarter?
BioAtla released its earnings results on Aug 07, 2025. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.28 by -$0.04.
Is BioAtla overvalued?
According to Wall Street analysts BioAtla’s price is currently Undervalued.
Does BioAtla pay dividends?
BioAtla does not currently pay dividends.
What is BioAtla’s EPS estimate?
BioAtla’s EPS estimate is -0.3.
How many shares outstanding does BioAtla have?
BioAtla has 58,721,590 shares outstanding.
What happened to BioAtla’s price movement after its last earnings report?
BioAtla reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.28. Following the earnings report the stock price went down -7.895%.
Which hedge fund is a major shareholder of BioAtla?
Currently, no hedge funds are holding shares in BCAB
BioAtla Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10.00 (2464.10% Upside)
$10.00 (2464.10% Upside)
Blogger Sentiment
Bullish
BCAB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 76.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.57%
12-Months-Change
Fundamentals
Return on Equity
-813.88%
Trailing 12-Months
Asset Growth
-60.48%
Trailing 12-Months
Company Description
BioAtla
BioAtla, Inc. (BCAB) is a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics. The company operates primarily in the biopharmaceutical sector, leveraging its proprietary CAB technology to create therapies that are activated under specific physiological conditions, enhancing safety and efficacy. BioAtla's core products include a pipeline of CAB antibody candidates aimed at treating various cancers, with a focus on improving patient outcomes through innovative therapeutic solutions.
BCAB Company Deck
BCAB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented notable scientific and regulatory advancements, particularly with BA3182 and Oz-V, and strategic partnerships aimed at non-dilutive funding. However, financial constraints, including decreased cash reserves and ongoing net losses, underline significant operational challenges.View all BCAB earnings summariesBCAB Stock 12 Month Forecast
Average Price Target
$10.00
▲(2464.10% Upside)
Technical Analysis
Lisata Therapeutics
―
ImmunoPrecise Antibodies
―
Elevation Oncology
―
ProMIS Neurosciences
―
Ownership Overview
9.38% Insiders
4.13% Mutual Funds
11.87% Other Institutional Investors
70.21% Public Companies and
Individual Investors